DelveInsight’s ‘COVID-19 (Novel Coronavirus 19) - Therapeutic Pipeline for Vaccines - 2020’ report provides comprehensive insights about 50+ companies and 60+ Vaccine based products in Covid-19 pipeline landscape. It covers the pipeline vaccine profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
COVID-19 (Novel Coronavirus 19) and Therapeutic Vaccines: Overview
The pneumonia caused by novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 is a highly contagious disease. The World Health Organization (WHO) has declared the ongoing outbreak as a global public health emergency.Currently, the research on novel coronavirus is still in the primary stage. In late December 2019, a case of unidentified pneumonia was reported in Wuhan, Hubei Province, People's Republic of China (PRC). Its clinical characteristics are very similar to those of viral pneumonia. After analysis on respiratory samples, PRC Centers for Disease Control (CDC) experts declared that the pneumonia, later known as novel coronavirus pneumonia (NCP), was caused by novel coronavirus.
To date, there is no approved targeted treatment, and many investigational therapeutic agents and vaccine candidates are being considered for the treatment of COVID-19. The availability of a safe and effective vaccine for COVID-19 is well-recognized as an additional tool to contribute to the control of the pandemic. At the same time, the challenges and efforts needed to rapidly develop, evaluate and produce this at scale are enormous. It is vital that as many vaccines as possible are evaluated as it cannot be predicted how many will turn out to be viable.
To increase the chances of success (given the high level of attrition during vaccine development), all candidate vaccines must be tested until they fail. WHO is working to ensure that all of them have the chance of being tested at the initial stage of development.
This segment of the COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines report encloses its detailed analysis of various vaccines in different stages of clinical development, including phase III, I/II, and I. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included vaccine, and the latest news and press releases.
Inovio Pharmaceuticals has begun human clinical trials on their coronavirus vaccine INO-4800 in April 2020. Results from the clinical trials are expected to be available in September 2020. Inovio aims to produce one million doses of the vaccine by the end of 2020 to perform additional clinical trials and/or emergency use of the vaccine. In 10 weeks from funding, INOVIO has manufactured thousands of doses of INO-4800 to support on-going Phase 1 and planned Phase II clinical trials. In parallel, INOVIO is working to scale up the manufacturing of INO-4800. INOVIO plans to have one million doses of the vaccine available by year-end for additional trials and emergency use, pending appropriate regulatory guidance and funding.
CanSino Biologics Inc. is developing Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) candidate Ad5-nCoV in phase II stage of development for the treatment of COVID-19. It is co-developed with Beijing Institute of Biotechnology (BIB). It is currently the first novel coronavirus vaccine for COVID-19 that made to this stage in China. The vaccine candidate is built upon CanSinoBIO’s adenovirus-based viral vector vaccine technology platform, which has also been successfully applied to develop the globally innovative vaccine against Ebola virus infection. Results from preclinical animal studies of Ad5-nCoV show that the vaccine candidate can induce strong immune response in animal models. The preclinical animal safety studies demonstrated a good safety profile.
mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for the Phase II clinical trial. This investigational vaccine was developed using messenger RNA (mRNA) and should direct the body’s cells to express a virus protein that hopefully will elicit a robust immune response, having shown promise in animal models.
Vaccitech’s VTP-500 MERS vaccine utilizes the ChAdOx1 virus platform to encode MERS coronavirus spike protein in order to induce T cells, but also antibodies which block virus-host cell receptor binding and fusion or neutralize virus infection. This program has been partnered with University Of Oxford, Janssen and CEPI. The vaccine has now been manufactured according to GMP practice and has been successfully tested in a Phase 1 clinical trial at Oxford University. CEPI, Oxford University and Janssen have entered into a collaboration worth up to $19M to progress the vaccine through Phase 2 studies and establish a human vaccine stockpile. Vaccitech retains commercial rights for the product while licensing certain rights back to Oxford for non-profit development of the vaccine.
Immunitor is developing therapeutic vaccine V-SARS which is formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunteers for at least one month. It is currently in phase I/II stage of development.
In May 2020, Immunitor initiated phase I/II trial titled “clinical trial of COVID-19 therapeutic vaccine formulated as an oral pill”. The goal of this trial is test safety and immunogenicity of once-per-day day administered orally to volunteers for 15 days. Baseline and post-treatment standard safety parameters will be compared. Blood samples from volunteers will be monitored and immunogenicity lab assays will be undertaken to characterize immune response. The trial is currently in active, not recruiting stage with estimated enrollment of 20 participants and expected to be completed in June 2021.
Novavax is developing SARS-CoV-2 rS nanoparticle vaccine for the treatment of patients with COVID-19 infections. 2019nCoV-101 is a 2-part, randomized, observer-blinded, placebo-controlled, Phase 1/2 trial designed to evaluate the immunogenicity and safety of SARS-CoV-2 rS nanoparticle vaccine with or without Matrix-M adjuvant in healthy participants ≥ 18 to 59 (inclusive) years of age. The study will be conducted in 2 parts. In Part 1, at least 1 and up to two SARS-CoV-2 rS constructs will be evaluated in up to 2 cohorts, which may be enrolled in parallel.
An interim analysis of Part 1 safety and immunogenicity data will be performed prior to an optional expansion to Part 2. This trial is expected to be completed by July 2021.
Further product details are provided in the report…
This segment of the report provides insights about the different Covid-19 emerging vaccines segregated based on following parameters that define the scope of the report, such as:
There are approx. 50+ key companies which are developing the therapies for Covid-19. The companies which have their Covid-19 vaccine candidates in the most advanced stage, i.e. Phase-III, include, Verity Pharmaceuticals and Immodulon Therapeutics Ltd.
DelveInsight’s report covers around 50+ products under different phases of clinical development like
COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Vaccines have been categorized under various types such as
The report provides insights into different therapeutic candidates in Phase III, and Phase I/II stage. It also analyses COVID-19 (Novel Coronavirus 19) therapeutic vaccines key players involved in developing key vaccines.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging COVID-19 (Novel Coronavirus 19) therapeutic Vaccines.
To keep up with current market trends, we take KOLs and SME’s opinion working in COVID-19 (Novel Coronavirus 19) therapeutic vaccines domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Current Treatment Scenario and Emerging Therapies:
1. Report Introduction
2. Key Insights
3. Disease Background and Overview: Coronavirus Disease 2019 (COVID-19)
3.1. Introduction
3.2. Classification of Coronavirus
3.3. Genetic structure and pathogenic mechanism of SARS-CoV-2 (COVID 19)
3.4. Risk Factors
3.5. Modes of Transmission: implications for IPC precaution recommendations
3.5.1. Droplet transmission
3.5.2. Airborne transmission
3.6. Signs and symptoms
3.7. Pathogenesis
4. Emerging Therapeutics
4.1. Vaccines
4.1.1. Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector): CanSino Biologics Inc.
4.1.1.1. Vaccine Description
4.1.1.2. Regulatory Milestones
4.1.1.3. Clinical Development
4.1.1.4. Product Profile
4.1.1.5. Clinical Pipeline Activity
4.1.1.5.1. Ongoing Trials Information
4.1.1.5.2. Clinical Trials by Phase
4.1.1.5.3. Safety and Efficacy
4.1.2. mRNA-1273 vaccine: Moderna
4.1.2.1. Vaccine Description
4.1.2.2. Regulatory Milestones
4.1.2.3. Clinical Development
4.1.2.4. Product Profile
4.1.2.5. Clinical Pipeline Activity
4.1.2.5.1. Ongoing Trials Information
4.1.2.5.2. Clinical Trials by Phase
4.1.2.5.3. Safety and Efficacy
4.1.3. Matrix-M: Novavax
4.1.3.1. Vaccine Description
4.1.3.2. Regulatory Milestones
4.1.3.3. Clinical Development
4.1.3.4. Product Profile
4.1.3.5. Clinical Pipeline Activity
4.1.3.5.1. Ongoing Trials Information
4.1.3.5.2. Clinical Trials by Phase
4.1.3.5.3. Safety and Efficacy
4.1.2. mRNA-1273 vaccine: Moderna
4.1.2.1. Vaccine Description
4.1.2.2. Regulatory Milestones
4.1.2.3. Clinical Development
4.1.2.4. Product Profile
4.1.2.5. Clinical Pipeline Activity
4.1.2.5.1. Ongoing Trials Information
4.1.2.5.2. Clinical Trials by Phase
4.1.2.5.3. Safety and Efficacy
4.1.3. Matrix-M: Novavax
4.1.3.1. Vaccine Description
4.1.3.2. Regulatory Milestones
4.1.3.3. Clinical Development
4.1.3.4. Product Profile
4.1.3.5. Clinical Pipeline Activity
4.1.3.5.1. Ongoing Trials Information
4.1.3.5.2. Clinical Trials by Phase
4.1.3.5.3. Safety and Efficacy
4.1.4. Virus-Like Particle (VLP) Based Vaccine: Medicago
4.1.4.1. Vaccine Description
4.1.4.2. Regulatory Milestones
4.1.4.3. Clinical Development
4.1.4.4. Product Profile
4.1.4.5. Clinical Pipeline Activity
4.1.4.5.1. Ongoing Trials Information
4.1.4.5.2. Clinical Trials by Phase
4.1.4.5.3. Safety and Efficacy
4.1.5. Coronavirus vaccine INO-4800: Inovio Pharmaceuticals
4.1.5.1. Vaccine Description
4.1.5.2. Regulatory Milestones
4.1.5.3. Clinical Development
4.1.5.4. Product Profile
4.1.5.5. Clinical Pipeline Activity
4.1.5.5.1. Ongoing Trials Information
4.1.5.5.2. Clinical Trials by Phase
4.1.5.5.3. Safety and Efficacy
4.1.6. BNT162: BioNTech
4.1.6.1. Vaccine Description
4.1.6.3. Clinical Development
4.1.6.4. Product Profile
4.1.6.5. Clinical Pipeline Activity
4.1.6.5.1. Ongoing Trials Information
4.1.6.5.2. Clinical Trials by Phase
4.1.6.5.3. Safety and Efficacy
List to be continued in the report…………………
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Route of Administration
5.1.2.1. Assessment by Stage and Route of Administration
5.1.3. Assessment by Vaccine Type
5.1.3.1. Assessment by Stage and Vaccine Type
6. COVID-19 – DelveInsight’s Analytical Perspective
6.1. In-depth Commercial Assessment
6.1.1. COVID-19 companies’ collaborations, Licensing, Acquisition -Deal Value Trends
6.2. COVID-19 Collaboration Deals
6.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
6.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
7. Other Emerging Pipeline Therapeutic Options for Covid-19
7.1. Monoclonal Antibodies
7.1.1. Sarilumab: Regeneron Pharmaceuticals
7.1.2. Tocilizumab (TCZ): Hoffmann-La Roche
List to be continued in the report…………………
7.2. Other Biologics
7. 2.1. NestCell: Azidus Brasil
List to be continued in the report…………………
7.3. Small Molecules
7.3.1. Remdesivir: Gilead Sciences
7.3.2. Hydroxychloroquine: Sanofi
List to be continued in the report…………………
7.4. Others
7.4.1. PUL-042 Inhalation Solution: Pulmotect, Inc.
7.4.2. DAS181: Ansun Biopharma
List to be continued in the report…………………
8. Key Trends and Developments
9. SWOT Analysis
10. Market Drivers
11. Market Barriers
12. Unmet Needs
13. Appendix
14. Report Methodology
14.1. Sources Used
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
List of Table
Table 1 Total Vaccine Products for COVID 19
Table 2 Assessment by Route of Administration
Table 3 Assessment by Stage and Route of Administration
Table 4 Assessment by Vaccine Type
Table 5 Assessment by Stage and Vaccine Type
Table 6 COVID-19 companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Table 7 COVID-19 Collaboration Deals
Table 8 Company-Company Collaborations (Licensing / Partnering) Analysis
Table 9 Company-University Collaborations (Licensing / Partnering) Analysis
Table 10 Market Drivers and Barriers
Table 11 SWOT Analysis
Table 12 Unmet Needs
Table of Figure
Figure 1 Total Vaccine Products for COVID 19
Figure 2 Assessment by Route of Administration
Figure 3 Assessment by Stage and Route of Administration
Figure 4 Assessment by Vaccine Type
Figure 5 Assessment by Stage and Vaccine Type
Figure 6 COVID-19 companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Figure 7 COVID-19 Collaboration Deals
Figure 8 Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 9 Company-University Collaborations (Licensing / Partnering) Analysis
Figure 10 Market Drivers and Barriers
Figure 11 SWOT Analysis
Figure 12 Unmet Needs
• AdaptVac
• Aivita Biomedical, Inc.
• Altimmune
• Anhui Zhifei Longcom Biopharmaceutical
• Arcturus Therapeutics
• AstraZeneca
• Bharat Biotech
• BioNTech / Pfizer / Fosun Pharma
• CanSino Biologics
• Clover Biopharmaceuticals / GSK / Dynavax
• Codagenix
• CureVac
• Daiichi Sankyo
• Fabentech
• FluGen and Bharat Biotech
• GeneCure
• GeneOne Life Science
• Genexine, Inc.
• GeoVax
• Greffex
• Heat Biologics
• iBio/Beijing CC Pharming
• "Immodulon Therapeutics Ltd.
• BioCan Rx
• ATGen Canada Inc."
• Immunitor
• ImmunityBio
• Immunovative Therapies, Ltd.
• IMV, Inc.
• Inovio Pharmaceuticals
• Janssen Pharmaceuticals
• Medicago (A subsidiary of Mitsubishi Tanabe Pharma Corporation)
• Merck / IAVI
• Moderna
• Novartis
• Novavax
• NuGenerex (A subsidiary of Generex)
• Panacea Biotec
• ReiThera (Italy), Leukocare (Germany), Univer cells (Belgium)
• Sanofi
• Sanofi pasteur
• Serum Institute of India
• Sinopharm
• Sinovac Biotech
• Sorrento Therapeutics
• Suzhou Abogen Biosciences and Walvax Biotechnology
• Symvivo Corporation
• Takis Biotech
• Vaccitech
• Valneva
• Vaxart
• Vaxine
• VBI Vaccines
• Verity Pharmaceuticals
• VIDO-InterVac
